Literature DB >> 34055225

Discovery of 5-Nitro-6-thiocyanatopyrimidines as Inhibitors of Cryptococcus neoformans and Cryptococcus gattii.

Maureen J Donlin1,2, Thomas R Lane3, Olga Riabova4, Alexander Lepioshkin4, Evan Xu1, Jeffrey Lin4, Vadim Makarov5, Sean Ekins3.   

Abstract

Opportunistic infections from pathogenic fungi present a major challenge to healthcare because of a very limited arsenal of antifungal drugs, an increasing population of immunosuppressed patients, and increased prevalence of resistant clinical strains due to overuse of the few available antifungals. Cryptococcal meningitis is a life-threatening opportunistic fungal infection caused by one of two species in the Cryptococcus genus, Cryptococcus neoformans and Cryptococcus gattii. Eighty percent of cryptococcosis diseases are caused by C. neoformans that is endemic in the environment. The standard of care is limited to old antifungals, and under a high standard of care, mortality remains between 10 and 30%. We have identified a series of 5-nitro-6-thiocyanatopyrimidine antifungal drug candidates using in vitro and computational machine learning approaches. These compounds can inhibit C. neoformans growth at submicromolar levels, are effective against fluconazole-resistant C. neoformans and a clinical strain of C. gattii, and are not antagonistic with currently approved antifungals.
© 2021 American Chemical Society.

Entities:  

Year:  2021        PMID: 34055225      PMCID: PMC8155264          DOI: 10.1021/acsmedchemlett.1c00038

Source DB:  PubMed          Journal:  ACS Med Chem Lett        ISSN: 1948-5875            Impact factor:   4.345


  41 in total

1.  Epidemiology and outcome of invasive fungal infections in solid organ transplant recipients.

Authors:  D Neofytos; J A Fishman; D Horn; E Anaissie; C-H Chang; A Olyaei; M Pfaller; W J Steinbach; K M Webster; K A Marr
Journal:  Transpl Infect Dis       Date:  2010-01-25       Impact factor: 2.228

2.  Management of cryptococcal meningitis in AIDS: the need for specific studies in developing countries.

Authors:  Olivier Lortholary
Journal:  Clin Infect Dis       Date:  2007-05-25       Impact factor: 9.079

3.  Multiple Machine Learning Comparisons of HIV Cell-based and Reverse Transcriptase Data Sets.

Authors:  Kimberley M Zorn; Thomas R Lane; Daniel P Russo; Alex M Clark; Vadim Makarov; Sean Ekins
Journal:  Mol Pharm       Date:  2019-02-26       Impact factor: 4.939

4.  The prevalence, clinical features, risk factors and outcome associated with cryptococcal meningitis in HIV positive patients in Kenya.

Authors:  R Mdodo; K Brown; E Omonge; W Jaoko; J Baddley; P Pappas; M Colette Kempf; I Aban; S Odera; A Suleh; P E Jolly
Journal:  East Afr Med J       Date:  2010-12

5.  A high-throughput screening assay for fungicidal compounds against Cryptococcus neoformans.

Authors:  Jennifer L A Rabjohns; Yoon-Dong Park; Jean Dehdashti; Christina Henderson; Adrian Zelazny; Steven J Metallo; Wei Zheng; Peter R Williamson
Journal:  J Biomol Screen       Date:  2013-07-29

Review 6.  Invasive fungal infections in solid organ transplant recipients.

Authors:  Shmuel Shoham; Kieren A Marr
Journal:  Future Microbiol       Date:  2012-05       Impact factor: 3.165

7.  Open Source Bayesian Models. 1. Application to ADME/Tox and Drug Discovery Datasets.

Authors:  Alex M Clark; Krishna Dole; Anna Coulon-Spektor; Andrew McNutt; George Grass; Joel S Freundlich; Robert C Reynolds; Sean Ekins
Journal:  J Chem Inf Model       Date:  2015-06-03       Impact factor: 4.956

8.  Cryptococcus gattii VGIII isolates causing infections in HIV/AIDS patients in Southern California: identification of the local environmental source as arboreal.

Authors:  Deborah J Springer; R Blake Billmyre; Elan E Filler; Kerstin Voelz; Rhiannon Pursall; Piotr A Mieczkowski; Robert A Larsen; Fred S Dietrich; Robin C May; Scott G Filler; Joseph Heitman
Journal:  PLoS Pathog       Date:  2014-08-21       Impact factor: 6.823

9.  Prevalence and correlates of cryptococcal antigen positivity among AIDS patients--United States, 1986-2012.

Authors:  Jennie McKenney; Rachel M Smith; Tom M Chiller; Roger Detels; Audrey French; Joseph Margolick; Jeffrey D Klausner
Journal:  MMWR Morb Mortal Wkly Rep       Date:  2014-07-11       Impact factor: 17.586

10.  In Vitro and In Vivo Evaluation of APX001A/APX001 and Other Gwt1 Inhibitors against Cryptococcus.

Authors:  Karen Joy Shaw; Wiley A Schell; Jonathan Covel; Gisele Duboc; C Giamberardino; Mili Kapoor; Molly Moloney; Quinlyn A Soltow; Jennifer L Tenor; Dena L Toffaletti; Michael Trzoss; Peter Webb; John R Perfect
Journal:  Antimicrob Agents Chemother       Date:  2018-07-27       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.